Usage Information
Citation Information: JCI Insight. 2021;6(9):e148435. https://doi.org/10.1172/jci.insight.148435.
Abstract
SARS coronavirus 2 (SARS-CoV-2) is a novel viral pathogen that causes a clinical disease called coronavirus disease 2019 (COVID-19). Although most COVID-19 cases are asymptomatic or involve mild upper respiratory tract symptoms, a significant number of patients develop severe or critical disease. Patients with severe COVID-19 commonly present with viral pneumonia that may progress to life-threatening acute respiratory distress syndrome (ARDS). Patients with COVID-19 are also predisposed to venous and arterial thromboses that are associated with a poorer prognosis. The present study identified the emergence of a low-density inflammatory neutrophil (LDN) population expressing intermediate levels of CD16 (CD16Int) in patients with COVID-19. These cells demonstrated proinflammatory gene signatures, activated platelets, spontaneously formed neutrophil extracellular traps, and enhanced phagocytic capacity and cytokine production. Strikingly, CD16Int neutrophils were also the major immune cells within the bronchoalveolar lavage fluid, exhibiting increased CXCR3 but loss of CD44 and CD38 expression. The percentage of circulating CD16Int LDNs was associated with D-dimer, ferritin, and systemic IL-6 and TNF-α levels and changed over time with altered disease status. Our data suggest that the CD16Int LDN subset contributes to COVID-19–associated coagulopathy, systemic inflammation, and ARDS. The frequency of that LDN subset in the circulation could serve as an adjunct clinical marker to monitor disease status and progression.
Authors
Samantha M. Morrissey, Anne E. Geller, Xiaoling Hu, David Tieri, Chuanlin Ding, Christopher K. Klaes, Elizabeth A. Cooke, Matthew R. Woeste, Zachary C. Martin, Oscar Chen, Sarah E. Bush, Huang-ge Zhang, Rodrigo Cavallazzi, Sean P. Clifford, James Chen, Smita Ghare, Shirish S. Barve, Lu Cai, Maiying Kong, Eric C. Rouchka, Kenneth R. McLeish, Silvia M. Uriarte, Corey T. Watson, Jiapeng Huang, Jun Yan
Usage data is cumulative from January 2024 through January 2025.
| Usage | JCI | PMC |
|---|---|---|
| Text version | 1,387 | 638 |
| 100 | 88 | |
| Figure | 363 | 13 |
| Supplemental data | 41 | 19 |
| Citation downloads | 43 | 0 |
| Totals | 1,934 | 758 |
| Total Views | 2,692 | |
Usage information is collected from two different sources: this site (JCI) and Pubmed Central (PMC). JCI information (compiled daily) shows human readership based on methods we employ to screen out robotic usage. PMC information (aggregated monthly) is also similarly screened of robotic usage.
Various methods are used to distinguish robotic usage. For example, Google automatically scans articles to add to its search index and identifies itself as robotic; other services might not clearly identify themselves as robotic, or they are new or unknown as robotic. Because this activity can be misinterpreted as human readership, data may be re-processed periodically to reflect an improved understanding of robotic activity. Because of these factors, readers should consider usage information illustrative but subject to change.
